Bone marrow dendritic cells are reduced in patients with high-risk myelodysplastic syndromes

CD1c(+) myeloid dendritic cells in myeloid neoplasia

“…The mean percentage of CD1c(+) MDCs in bone marrow determined was 0.08% ± 0.03% (range 0.027–0.178%). The relative proportion of CD1c(+) MDCs in the marrow, therefore, appears slightly lower than that in peripheral blood and is in close agreement with a previous report .…”

“…Previous studies of MDCs in MDS have also suggested that MDCs are decreased in dyplastic disorders . Notably Saft et al observed a mean of 0.025% MDCs compared to 0.08% in controls in close agreement with our results and no patient was noted to have more than 0.14% MDCs .…”

Chronic immune response dysregulation in MDS pathogenesis

“…The role of granulocytes, macrophages, and dendritic cells is less clear in MDS. [86][87][88] As indicated previously, deletion of mDia1 or TET2 results in increased innate immune signaling in mature myeloid cells. The contribution of the adaptive immune system, specifically T-cell surveillance, in MDS BM has not been as extensively documented.…”

Clinical Implication of Multi-Parameter Flow Cytometry in Myelodysplastic Syndromes

“…Several other hematopoietic cell subsets, involved in the dysplastic clone and/or in the immunopathogenesis of MDS, have been described, including aberrancies in mast cells, changes of frequency in plasmacytoid dendritic cells, myeloid dendritic cells (mDC1 and mDC2), myeloid-derived suppressor cells (MDSC) and T cell subsets [24,25]. Increased frequencies of MDSCs and T-regulatory cells are thought to reflect an immunosuppressive environment in high risk MDS [2,26].…”